CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bristow, C. L.
Right arrow Articles by Arnold, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bristow, C. L.
Right arrow Articles by Arnold, R. R.

Clinical and Diagnostic Laboratory Immunology, September 2001, p. 937-942, Vol. 8, No. 5
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.5.937-942.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Self Antigen Prognostic for Human Immunodeficiency Virus Disease Progression

Cynthia L. Bristow,1,* Hirenkumar Patel,2 and Roland R. Arnold2

Department of Pathology and Laboratory Medicine1 and Dental Research Center,2 University of North Carolina---Chapel Hill, Chapel Hill, North Carolina 27514

Received 26 February 2001/Returned for modification 23 April 2001/Accepted 24 May 2001

We have recently found that an extracellular protein, alpha 1 proteinase inhibitor (alpha 1PI; alpha 1 antitrypsin), is required for in vitro human immunodeficiency virus (HIV) infectivity outcome. We show here in a study of HIV-seropositive patients that decreased viral load is significantly correlated with decreased circulating alpha 1PI. In the asymptomatic category of HIV disease, 100% of patients manifest deficient levels of active alpha 1PI, a condition known to lead to degenerative lung diseases and a dramatically reduced life span. Further, HIV-associated alpha 1PI deficiency is correlated with circulating anti-alpha 1PI immunoglobulin G. These results suggest that preventing HIV-associated alpha 1PI deficiency may provide a strategic target for preventing HIV-associated pathophysiology.

* Corresponding author. Present address: Rockefeller University, Laboratory of Cellular Physiology and Immunology, 1230 York Ave., Box 176, New York, NY 10021. Phone: (212) 327-7795. Fax: (212) 327-7764. E-mail: bristoc{at}mail.rockefeller.edu.

Clinical and Diagnostic Laboratory Immunology, September 2001, p. 937-942, Vol. 8, No. 5
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.5.937-942.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.